Nevertheless, the international guidelines have included the use of pioglitazone, a peroxisome proliferator-activated receptor (PPAR) agonist, and/or vitamin E to specifically treat NASH patients (Table 3 and Table 4). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.